Zoledronic acid administration failed to prevent bone loss at the knee in persons with acute spinal cord injury: an observational cohort study

After acute spinal cord injury (SCI), rapid depletion of the sublesional skeleton occurs, particularly at the distal femur and proximal tibia. Subsequently, fragility fractures of the knee may occur. We determined the efficacy of zoledronic acid to prevent sublesional bone mineral density (BMD) loss...

Full description

Saved in:
Bibliographic Details
Published in:Journal of bone and mineral metabolism 2015-07, Vol.33 (4), p.410-421
Main Authors: Bauman, William A., Cirnigliaro, Christopher M., La Fountaine, Michael F., Martinez, LeighAnn, Kirshblum, Steven C., Spungen, Ann M.
Format: Article
Language:English
Subjects:
Absorptiometry, Photon
Adolescent
Adult
Bone and Bones - diagnostic imaging
Bone and Bones - pathology
Bone Density - drug effects
Bone Diseases, Metabolic - complications
Bone Diseases, Metabolic - prevention & control
Diphosphonates - administration & dosage
Female
Femur - diagnostic imaging
Femur - pathology
Humans
Imidazoles - administration & dosage
Knee - diagnostic imaging
Knee - pathology
Male
Medicine
Medicine & Public Health
Metabolic Diseases
Middle Aged
Original Article
Orthopedics
Prospective Studies
Spinal Cord Injuries - complications
Spinal Cord Injuries - drug therapy
Tibia - diagnostic imaging
Tibia - pathology
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:After acute spinal cord injury (SCI), rapid depletion of the sublesional skeleton occurs, particularly at the distal femur and proximal tibia. Subsequently, fragility fractures of the knee may occur. We determined the efficacy of zoledronic acid to prevent sublesional bone mineral density (BMD) loss at 6 and 12 months after acute SCI. Thirteen subjects with acute motor-complete SCI were prospectively studied: 6 patients received zoledronic acid (5 mg) and 7 subjects did not receive the drug (controls). Zoledronic acid was administered intravenously within 16 weeks of acute injury. Areal BMD was performed by dual energy X-ray absorptiometry at baseline, 6, and 12 months after administration of drug. The treatment group demonstrated sparing of BMD at the total hip at month 6 ( p  
ISSN:0914-8779
1435-5604
DOI:10.1007/s00774-014-0602-x